Banco de Sabadell S.A grew its stake in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 17.1% in the fourth quarter, HoldingsChannel reports. The fund owned 6,942 shares of the medical instruments supplier’s stock after acquiring an additional 1,015 shares during the period. Banco de Sabadell S.A’s holdings in Becton, Dickinson and were worth $1,751,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Accel Wealth Management raised its stake in shares of Becton, Dickinson and by 100.0% in the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 50 shares during the last quarter. Sierra Capital LLC grew its position in shares of Becton, Dickinson and by 88.7% during the 4th quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period. Level Financial Advisors Inc. acquired a new stake in shares of Becton, Dickinson and during the 4th quarter worth approximately $26,000. Fortis Advisors LLC acquired a new stake in shares of Becton, Dickinson and during the 3rd quarter worth approximately $27,000. Finally, Eagle Bay Advisors LLC grew its position in shares of Becton, Dickinson and by 64.9% during the 3rd quarter. Eagle Bay Advisors LLC now owns 155 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 61 shares during the period. 86.58% of the stock is owned by institutional investors.
Becton, Dickinson and stock opened at $256.46 on Friday. The stock has a market capitalization of $73.11 billion, a PE ratio of 40.45, a price-to-earnings-growth ratio of 4.15 and a beta of 0.64. Becton, Dickinson and Company has a twelve month low of $235.13 and a twelve month high of $280.62. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average of $259.71 and a 200-day moving average of $258.00.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be given a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio is presently 54.89%.
In other news, EVP David Hickey sold 475 shares of the business’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $256.00, for a total value of $121,600.00. Following the sale, the executive vice president now owns 3,806 shares of the company’s stock, valued at $974,336. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.50% of the company’s stock.
BDX has been the subject of several analyst reports. Morgan Stanley lifted their price target on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research report on Monday, April 11th. Argus boosted their price objective on shares of Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a report on Friday, April 1st. Piper Sandler decreased their price objective on shares of Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. Finally, SVB Leerink boosted their price objective on shares of Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a report on Friday, February 4th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $276.43.
Becton, Dickinson and Company Profile (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.